Immuneering Added to the Nasdaq Biotechnology Index
December 16 2021 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced that it will be added to the Nasdaq
Biotechnology Index (Nasdaq: NBI) effective prior to the market
open on Monday, December 20, 2021.
The Nasdaq Biotechnology Index (NBI) is designed to measure the
performance of a set of securities listed on the Nasdaq Stock
Market that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
(ICB). The NBI is calculated under a modified market
capitalization-weighted methodology. Companies in the NBI must meet
eligibility requirements, including minimum market capitalization,
average daily trading volume and seasoning as a public company,
among other criteria. Nasdaq selects constituents once annually in
December. For more information about the NBI, please visit
https://indexes.nasdaqomx.com/Index/Overview/NBI.
“Immuneering’s addition to the NBI, less than five months after
our upsized initial public offering, is a welcome development which
will help to expand our visibility within the investment
community,” said Ben Zeskind, Ph.D., Immuneering’s Co-Founder,
President and Chief Executive Officer. “IMM-1-104 has demonstrated
tumor growth inhibition across 5 different animal models each
driven by a different RAS or RAF mutation. We are honored by the
excitement investors have shown for IMM-1-104 and our earlier stage
programs, all driven by translational bioinformatics. Our inclusion
in the NBI reflects the strength of our pipeline and our platform,
and we remain focused on executing our plans to advance IMM-1-104
and the rest of our pipeline.”
About Immuneering
Corporation
Immuneering is a biopharmaceutical company with an emerging
pipeline focused on improving patient outcomes across a spectrum of
debilitating oncologic and neurologic diseases by applying its deep
knowledge of translational bioinformatics to every stage of the
drug development process. Immuneering has more than a decade of
experience in translational bioinformatics and generating insights
into drug mechanisms of action and patient treatment responses.
Building on this experience, Immuneering has developed a
disease-agnostic platform that enables the company to utilize human
data, novel biology and chemistry, and translational planning to
create and advance its wholly owned pipeline. Immuneering’s current
development programs in oncology are focused on providing potential
treatments for patients with solid tumors caused by mutations of
oncologic signaling pathways, including the MAPK pathway.
Immuneering’s lead product candidate, IMM-1-104, is designed to be
a highly selective dual-MEK inhibitor that further disrupts KSR for
the treatment of advanced solid tumors in patients harboring RAS
mutant tumors. Additionally, Immuneering has six other oncology
programs in the discovery stage that are designed to target either
the MAPK or mTOR pathway, and two neuroscience programs in the
discovery
stage.
Forward-Looking Statements
This press release includes certain disclosures that contain
"forward-looking statements," including, without limitation,
statements regarding Immuneering’s progress toward drugs targeting
cancers driven by alterations that activate the RAS/MAPK pathway,
the treatment potential of IMM-1-104, and the strength of
Immuneering’s translational bioinformatics approach and technology
platform. Forward-looking statements are based on Immuneering’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Factors that
could cause actual results to differ include, but are not limited
to, the risks inherent in oncology and neuroscience drug
development, including target discovery, target validation, lead
compound identification, lead compound optimization, preclinical
studies and clinical trials. These and other risks and
uncertainties are described more fully in the section titled "Risk
Factors" in the Company’s most recent Form 10-Q filed with the U.S.
Securities and Exchange Commission (SEC) as well as in
Immuneering’s subsequent filings it makes with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Immuneering undertakes no duty to update such
information except as required under applicable law.
Corporate Contact:Rebecca Kusko, Ph.D.Immuneering
Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communicationssusan@sanoonan.com917-513-5303
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024